25 maart 2018: Lees ook dit artikel eens:

https://kanker-actueel.nl/weghalen-van-levertumoren-bij-geselecteerde-groep-patienten-met-uitgezaaide-borstkanker-geeft-langere-ziektevrije-tijd-en-betere-overall-overleving-op-5-jaar.html

25 augustus 2015: zie ook dit artikel:

nanoknife-irreversible-electroporation-blijkt-succesvolle-operatietechniek-te-zijn-bij-lokaal-uitgezaaide-alvleesklierkanker-slechts-6-procent-kreeg-recidief-op-25-jaar-meting

Klik op NTvG Nieuwe Technieken IRE voor een prachtig artikel met duidelijke foto's uit het Nederlands tijdschrift voor Geneeskunde van dr. Martijn Meyerink en arts-onderzoeker Hester Scheffer over de nanoknife - irreversible electroporation.

17 februari 2014: Bron: J Med Case Rep. 2013 May 13;7(1):128. doi: 10.1186/1752-1947-7-128

Tot nu toe worden alleen patiënten met tumoren niet groter in diameter dan ca. 5 - 7 cm. cm. toegelaten tot behandelingen met de nanoknife - irreversible electroporation. Toch worden ook soms patiënten met grotere tumoren in diameter behandeld. Zoals deze case studie in Duitsland. Een vrouw van 56 jaar met een recidief van buikvlieskanker met een grote tumor - omvang (11.9 × 11.6 × 14.9 cm) met ook nog doorgroei van de tumor in het heiligbeen en zenuwplexus werd toch nog behandeld met de nanoknife en met succes blijkt uit de studie omschrijving. Deze vrouw had nagenoeg geen blijvende schade door de behandeling met de nanoknife. Het volledige studierapport: Palliative treatment of presacral recurrence of endometrial cancer using irreversible electroporation: a case report is gratis in te zien. Hieronder het abstract van deze studie:

Studies met de nanoknife in Nederland zie gerelateerde artikelen.

A large tumor mass adjacent to a bundle of neural structures, the sacral plexus, can be widely ablated by irreversible electroporation with only minor temporary impairment of the neural function, even though a large infiltrating tissue volume (941cm3) was ablated

2013 May 13;7(1):128. doi: 10.1186/1752-1947-7-128.

Palliative treatment of presacral recurrence of endometrial cancer using irreversible electroporation: a case report.

Niessen C, Jung EM, Schreyer AG, Wohlgemuth WA, Trabold B, Hahn J, Rechenmacher M, Stroszczynski C, Wiggermann P.

Author information

Abstract

INTRODUCTION:

Irreversible electroporation (IRE) is a new minimally invasive tumor ablation technique which induces irreversible disruption of cell membrane integrity by changing the transmembrane potential resulting in cell death. Irreversible electroporation is currently undergoing clinical investigation as local tumor therapy for malignant liver and lung lesions. This is the first case report to describe the successful palliative ablation of a presacral recurrence of an endometrial cancer to achieve locoregional tumor control and pain relief.

CASE PRESENTATION:

A 56-year-old Caucasian woman was referred for interventional treatment of an advanced local recurrence of endometrial cancer (11.9 × 11.6 × 14.9cm) with infiltration of the sacral bone and nerve plexus. Due to the immediate proximity to the sacral plexus, the patient could neither undergo surgical therapy nor a second radiation therapy. Due to its ablation mechanism irreversible electroporation was deemed to be the best therapy option.

CONCLUSION:

We showed in this case that a large tumor mass adjacent to a bundle of neural structures, the sacral plexus, can be widely ablated by irreversible electroporation with only minor temporary impairment of the neural function, even though a large infiltrating tissue volume (941cm3) was ablated.

PMID:: 23668891
PMCID:: PMC3657545

References

Freeman SA, Wang MA, Weaver JC. Theory of electroporation of planar bilayer membranes: predictions of the aqueous area, change in capacitance, and pore-pore separation. Biophys J. 1994;7(1):42–56. doi: 10.1016/S0006-3495(94)80453-9. [PMC free article] [PubMed] [Cross Ref]
Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;7:611–621. doi: 10.1016/j.jvir.2010.12.014. [PubMed] [Cross Ref]
Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;7:33–64. doi: 10.3322/canjclin.49.1.33. [PubMed] [Cross Ref]
Amant F, Moerman P, Neven P, Timmermann D, Van Limbergen E, Vergote I. Treatment modalities in endometrial cancer. Curr Opin Oncol. 2007;7:479–485. doi: 10.1097/CCO.0b013e32827853c0. [PubMed] [Cross Ref]
Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat. 2007;7:287–294. [PubMed]
Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010;7(2):426–433. doi: 10.1148/radiol.10090337. [PubMed] [Cross Ref]
Onik G, Rubinsky B, Mikus P. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat. 2007;7:295–300. [PubMed]
Deodhar A, Dickfeld T, Single GW, Hamilton WC Jr, Thornton RH, Sofocleous CT, Maybody M, Gonen M, Rubinsky B, Solomon SB. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol. 2011;7:330–335. doi: 10.2214/AJR.10.4490. [PubMed] [Cross Ref]
Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;7:43–58. doi: 10.1148/radiol.11110144. [PubMed] [Cross Ref]
Mylona S, Karagiannis G, Patsoura S, Galani P, Pomoni M, Thanos L. Palliative treatment of rectal carcinoma recurrence using radiofrequency ablation. Cardiovasc Intervent Radiol. 2012;7:875–882. doi: 10.1007/s00270-011-0320-x. [PubMed] [Cross Ref]
Heller R. Overview of electroporation. 2002. Technol Cancer Res Treat. 2002;7:317–318. [PubMed]
Davalos R, Mir L, Rubinsky B. Tissue ablation with irreversible electroporation. Annals Biomed Eng. 2005;7:223–231. doi: 10.1007/s10439-005-8981-8. [PubMed] [Cross Ref]
Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat. 2005;7:699–706. [PubMed]
Ben-David E, Appelbaum L, Sosna J, Nissenbaum I, Goldberg SN. Characterization of irreversible electroporation ablation in in vivo porcine liver. Am J Roentgenol. 2012;7:W62–W68. doi: 10.2214/AJR.11.6940. [PubMed] [Cross Ref]
Lee RC. Cell injury by electric forces. Ann NY Acad Sci. 2005;7:85–91. doi: 10.1196/annals.1363.007. [PubMed] [Cross Ref]
Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat. 2007;7:307–312. [PubMed]
Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg. 1998;7:559–565. doi: 10.1097/00000658-199804000-00018. [PMC free article] [PubMed] [Cross Ref]
Charpentier KP. Irreversible electroporation for the ablation of liver tumors: are we there yet? Arch Surg – Chicago. 2012;7:1053–1061. doi: 10.1001/2013.jamasurg.100. [PubMed] [Cross Ref]
Kingham TP, Karkar AM, D’Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI, Sofocleous CT, Solomon SB, Jarnagin WR, Fong Y. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;7(3):379–387. doi: 10.1016/j.jamcollsurg.2012.04.029. [PubMed] [Cross Ref]